Medical Oncologist, Professor, Department of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB
Dr. Venner is a medical oncologist with a clinical practice focused on genitor-urinary malignancy. He has participated and lead innumerable clinical trials that have resulted in practice changing outcomes. Through mentoring of learners that are conducting clinical research and outcomes research he has helped foster the pursuit of academic prostate cancer research. Dr. Venner is actively engaged in fund raising and has been instrumental in the establishment of the prostate cancer research program and ongoing support of the program. He and his colleagues have a busy clinical practice and actively pursue interventional and translational research in an effort to improve the outcomes of patients with prostate cancer.
Relevant Publications
Wood L, Bjarnason GA, Black PC, Cagiannos I, Heng DY, Kapoor A, Kollmannsberger CK, Mohammadzadeh F, Moore RB, Rendon RA, Soulieres D, Tanguay S, Venner P, Jewett M, Finelli A. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract, 2013 Sep 1;9(5):e262-267. Epub 2013 Jun 4.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25. doi:10.1056/NEJMoa1212299.
Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, Canil C, Heng D, Reaume N, Tanguay S, Atkins M, Bjarnason G, Dancey J, Evans M, Fleshner N, Haider M, Kapoor A, Uzzo R, Maskens D, Soulieres D, Yousef G, Basappa N, Bendali N, Black P, Blais N, Cagiannos I, Care M, Chow R, Chung H, Czaykowski P, Derosa D, Durrant K, Ellard S, Farquharson G, Filion-Brulotte C, Gingerich J, Godbout L, Grant R, Hamilton W, Kassouf W, Kurban G, Lane K, Lattouf J, Lau D, Leveridge M, McCarthy J, Moore R, North S, O’brien P, Pituskin E, Racine P, Rendon R, So A, Sridhar S, Stubbs K, Su Z, Taylor L, Udall T, Venner P, Vogel W, Yap S, Yau P, Cooper M, Giroux N, Miron D, Mosher D, Ross K, Willacy J. Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can Urol Assoc J. 2012;6(1):(16-22)
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Venner P AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):(1187-97)
Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P as part of the Torward Optimized Practice Prostate Cancer Working Group. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J, December 2011, Volume 5, Issue 6
Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner P, Heidenreich A, Chu L, Heller G. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011 Jun 1;29(16):2191-8. Epub 2011 Apr 11.
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011 Jun 1;29(16):2171-7. Epub 2011 Apr 18.
Hotte SJ, Bjarsason GA, Heng DYC, Jewett MAS, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner P, Winquist EW, Wood L, Yong JHE, Saad F. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Current Oncology, Vol 18, supplement 2, S11-19.
Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko Y-J, Sridhar SS, Weber D, Saad F. A phase 2 study of patupilone in patient with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study PO7a. Annals of Oncology 2011; doi: 10.1093/annonc/mrd336.
Venner P. Genito-Urinary Tract cancer followup care. Oncology Exchange, Vol. 9, Nov. 4, November, 2010.
Miles BJ, Fairey AS, Eliasziw M, Estey EP, Venner P, Finch D, Trpkov K, Eigl BJ. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J. 2010 Aug:;4(4):263-7.
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010 Apr;4(2):e19-38.
Venner P. Cytoreductive nephrectomy: a treatment of the past. Can Urol Assoc J. 2010 Feb;4(1), 68-9.
Antoun S, Birdsell L, Sawyer M, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol, 2010
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi I, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Busowksi RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol, 2009 Dec 1:27(34):5794-9. Epub 2009 Oct 13
Hanninen M, Venner P, North S. A rapid PSA half-life following docetaxal chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J. October 2009, Vol 3, Issue 5, pp 369-74
Lefresne S, Fairchild A, Bistritz A, Venner P, Yee D. A case of indirect cauda equine syndrome from metastatic prostate cancer. Can Urol Assoc J. 2009 Augu;3(4):E31-E35.
Warren M, Venner P, North S, Cheng T, Venner C, Ghosh S, Venner AA, Finch D. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2009 Aug;3(4):281-289.
Fairey AS, Jacobsen N-E, Chetner MP, Mador DR, Metcalfe JB, Moore RB, Rourke KF, Todd GT, Venner P, Voaklanger DC, Estey EP. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy Database. J Urol. 2009 July;182(1):85-92; discussion 93.
Karvinen KH, Courneya KS, Plotnikoff RC, Spence JC, Venner P, North S. A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. Support Care Cancer. 2009 Feb;17(2):171-9.
Winquist E, Julian JA, Moore MJ, Nabid A, Sathya J, Wood L, Venner P, Levine M. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol. 2009 Feb 1;27(4):644-6.